MTM Laboratories Planning FDA Filings for Cervical Disease Tests | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Seeking to capitalize on what MTM Laboratories' CEO calls the "next-generation technology beyond HPV testing," the German diagnostics firm plans to file for regulatory approval in the US in the coming months for its assay for high-grade cervical disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.